New York State Common Retirement Fund Purchases 818 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)

New York State Common Retirement Fund grew its holdings in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 0.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 420,436 shares of the medical equipment provider’s stock after buying an additional 818 shares during the period. New York State Common Retirement Fund’s holdings in BioLife Solutions were worth $6,832,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of BLFS. Nisa Investment Advisors LLC grew its stake in shares of BioLife Solutions by 167.2% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,630 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 1,020 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of BioLife Solutions by 8.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,622 shares of the medical equipment provider’s stock worth $216,000 after acquiring an additional 1,164 shares during the last quarter. Conestoga Capital Advisors LLC increased its holdings in shares of BioLife Solutions by 4.2% during the fourth quarter. Conestoga Capital Advisors LLC now owns 64,847 shares of the medical equipment provider’s stock valued at $1,054,000 after acquiring an additional 2,585 shares in the last quarter. American Financial Group Inc. raised its position in shares of BioLife Solutions by 12.5% in the 3rd quarter. American Financial Group Inc. now owns 29,602 shares of the medical equipment provider’s stock worth $409,000 after purchasing an additional 3,286 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its position in shares of BioLife Solutions by 88.4% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 11,346 shares of the medical equipment provider’s stock worth $157,000 after purchasing an additional 5,324 shares during the last quarter. 93.24% of the stock is owned by hedge funds and other institutional investors.

BioLife Solutions Trading Down 0.7 %

Shares of NASDAQ:BLFS opened at $18.03 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.86 and a quick ratio of 1.83. BioLife Solutions, Inc. has a 1 year low of $8.92 and a 1 year high of $24.50. The company has a market cap of $816.76 million, a P/E ratio of -11.86 and a beta of 1.69. The stock’s fifty day moving average price is $17.37 and its 200-day moving average price is $15.64.

BioLife Solutions (NASDAQ:BLFS) last posted its earnings results on Thursday, February 29th. The medical equipment provider reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.02. BioLife Solutions had a negative net margin of 46.37% and a negative return on equity of 13.36%. The business had revenue of $32.73 million for the quarter, compared to analysts’ expectations of $32.70 million. Sell-side analysts expect that BioLife Solutions, Inc. will post -0.6 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group initiated coverage on shares of BioLife Solutions in a research note on Thursday, April 4th. They set a “buy” rating and a $22.00 price objective for the company. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $23.40.

Insider Buying and Selling

In other BioLife Solutions news, CEO Greef Roderick De sold 7,249 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $16.60, for a total transaction of $120,333.40. Following the completion of the sale, the chief executive officer now directly owns 461,854 shares in the company, valued at approximately $7,666,776.40. The sale was disclosed in a document filed with the SEC, which is available through this link. In related news, Director Amy Duross sold 6,135 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $16.86, for a total transaction of $103,436.10. Following the completion of the sale, the director now directly owns 34,508 shares in the company, valued at $581,804.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Greef Roderick De sold 7,249 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $16.60, for a total transaction of $120,333.40. Following the completion of the transaction, the chief executive officer now owns 461,854 shares in the company, valued at $7,666,776.40. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 33,996 shares of company stock worth $562,145. 2.70% of the stock is owned by insiders.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.